drugset / Trial / NCT00440609
Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of Ranibizumab in patients with Clinically Significant Diabetic Macular Edema (CSDME). It will also compare treatment outcomes for patients receiving 0.5mg Ranibizumab and higher doses of 1.0mg and 2.0mg Ranibizumab.
Timeline
- Start
- 2007-03
- Primary completion
- 2012-11
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ranibizumab | Monoclonal antibody | 0.5 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 1 mg | Intravitreal |
| Comparator | Ranibizumab | Monoclonal antibody | 2 mg | Intravitreal |